Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Assisted Reproduction and Genetics
Published in: Journal of Assisted Reproduction and Genetics 7/2011

01-07-2011 | Fertility Preservation

Treatment outcomes and quality-of-life assessment in a university-based fertility preservation program: Results of a registry of female cancer patients at 2 years

Authors: Andrea E. Reh, Lucy Lu, Rachel Weinerman, James Grifo, Lewis Krey, Nicole Noyes

Published in: Journal of Assisted Reproduction and Genetics | Issue 7/2011

Login to get access

Abstract

Purpose

To explore patient goals and quality of life (QOL) via a prospective registry and compare fertility preservation (FP) outcomes before, during, and after cancer therapy.

Methods

Of 35 patients entering the registry from 3/2008 to 3/2010, 29/35 completed the study survey and agreed to follow-up, and 31/35 completed treatment. Survey results and FP outcomes were analyzed.

Results

Most patients rated the impact of cancer treatment on fertility of highest importance at baseline and 1-year follow-up. QOL scores were overall positive at both intervals. Patients naïve to any cancer treatment (n = 12) had more gametes frozen than patients with prior cancer treatment (n = 19) with no difference in age or gonadotropin dosage. For patients awaiting cancer treatment, the median time from consultation to oocyte retrieval was 25 days. Cancer treatment sequalae posed challenges to optimal FP outcomes.

Conclusions

Fertility preservation remains a significant issue for cancer patients. With early reproductive endocrinologist referral, cancer treatment delay is minimized and FP outcomes are optimized.
Literature
1.
Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2006/​, based on November 2008 SEER data submission, posted to the SEER web site, 2009
2.
American Cancer Society. Cancer facts & figures 2010. Atlanta; 2010
3.
Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90:1635–9.PubMedCrossRef
4.
Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11:422–34.PubMedCrossRef
5.
Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17:2365–70.PubMed
6.
Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990;1:183–8.PubMed
7.
Bianco AR, Del Mastro L, Gallo C, Perrone F, Matano E, Pagliarulo C, et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991;63:799–803.PubMedCrossRef
8.
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718–29.PubMed
9.
Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997;43:183–90.PubMedCrossRef
10.
Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7:535–43.PubMedCrossRef
11.
Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from international breast cancer study group trials V to VI. Eur J Cancer. 2007;43:1646–53.PubMedCrossRef
12.
Porcu E, Fabbri R, Damiano G, Giunchi S, Fratto R, Ciotti PM, et al. Clinical experience and applications of oocyte cryopreservation. Mol Cell Endocrinol. 2000;169:33–7.PubMedCrossRef
13.
Chian RC, Huang JY, Gilbert L, Son WY, Holzer H, Cui SJ, et al. Obstetric and perinatal outcome in 200 infants conceived from vitrified oocytes. Reprod Biomed Online. 2008;16:608–10.PubMedCrossRef
14.
Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18:769–76.PubMedCrossRef
15.
Nagy ZP, Chang C, Shapiro D, Bernal D, Elsner C, Mitchell-Leef D, et al. Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking. Fertil Steril. 2009;92:520–6.PubMedCrossRef
16.
Cobo A, Meseguer M, Remohi J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25:2239–46.PubMedCrossRef
17.
Noyes N, Knopman J, Labella P, McCaffrey C, Clark-Williams M, Grifo J. Oocyte cryopreservation outcomes including pre-cryo and post-thaw meiotic spindle evaluation following slow cooling and vitrification of human oocytes. Fertil Steril. 2011;94:2078–82.CrossRef
18.
Ethics Committee of the ASRM. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83:1622–8.CrossRef
19.
Reinmuth S, Liebeskind AK, Wickmann L, Bockelbrink A, Keil T, Henze G, et al. Having children after surviving cancer in childhood or adolescence—results of a Berlin survey. Klin Pädiatr. 2008;220:159–65.PubMedCrossRef
20.
Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917–31.PubMedCrossRef
21.
Quinn GP, Vadaparampil ST, Bell-Ellison BA, Gwede CK, Albrecht TL. Patient-physician communication barriers regarding fertility preservation among newly diagnosed cancer patients. Soc Sci Med. 2008;66:784–9.PubMedCrossRef
22.
Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril. 2010;94:1652–6.PubMedCrossRef
23.
Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertil Steril. 2010;94:149–55.PubMedCrossRef
24.
Huyghe E, Sui D, Odensky E, Schover LR. Needs assessment survey to justify establishing a reproductive health clinic at a comprehensive cancer center. J Sex Med. 2009;6:149–63.PubMedCrossRef
25.
Peate M, Meiser B, Hickey M, Friedlander M. The fertility-related concerns, needs and preferences of younger women with breast cancer: a systematic review. Breast Cancer Res Treat. 2009;116:215–23.PubMedCrossRef
26.
Hammond CT, Beckjord EB, Arora NK, Bellizzi KM, Jeffery DD, Aziz NM. Non-Hodgkin’s lymphoma survivors’ fertility and sexual function-related information needs. Fertil Steril. 2008;90:1256–8.PubMedCrossRef
27.
Nayfield SG, Ganz PA, Moinpour CM, Cella DF, Hailey BJ. Report from a national cancer institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res. 1992;1:203–10.PubMedCrossRef
28.
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.PubMed
29.
Perry S, Kowalski TL, Chang CH. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes. 2007;5:24.PubMedCrossRef
30.
Grifo J, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2010;93:391–6.PubMedCrossRef
31.
Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril. 2009;91:1476–8.PubMedCrossRef
32.
Michaan N, Ben-David G, Ben-Yosef D, Almog B, Many A, Pauzner D, et al. Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients. Eur J Obstet Gynecol Reprod Biol. 2010;149:175–7.PubMedCrossRef
33.
Werner M, Reh A, Labella P, Noyes N. Laboratory evaluation in oocyte cryopreservation suggests retrieved oocytes are comparable whether frozen for medical indications, deferred reproduction or oocyte donation. J Assist Reprod Genet. 2010;27:613–7.PubMedCrossRef
34.
Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110:2222–9.PubMedCrossRef
35.
Dolmans MM, Demylle D, Martinez-Madrid B, Donnez J. Efficacy of in vitro fertilization after chemotherapy. Fertil Steril. 2005;83:897–901.PubMedCrossRef
36.
Kligman I, Noyes N, Benadiva CA, Rosenwaks Z. Massive deep vein thrombosis in a patient with antithrombin III deficiency undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 1995;63:673–6.PubMed
37.
Plante M, Renaud MC, Hoskins IA, Roy M. Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the literature. Gynecol Oncol. 2005;98:3–10.PubMedCrossRef
38.
Noyes N, Abu-Rustum MR, Ramarez P, Plante M. Options in the management of fertility-related issues in radical trachelectomy in patient with early cervical cancer. Gynecol Oncol. 2009;114:117–20.PubMedCrossRef
39.
Baynosa J, Westphal LM, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg. 2009;209:603–7.PubMedCrossRef
40.
Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–83.PubMedCrossRef
Metadata
Title
Treatment outcomes and quality-of-life assessment in a university-based fertility preservation program: Results of a registry of female cancer patients at 2 years
Authors
Andrea E. Reh
Lucy Lu
Rachel Weinerman
James Grifo
Lewis Krey
Nicole Noyes
Publication date
01-07-2011
Publisher
Springer US
Published in
Journal of Assisted Reproduction and Genetics / Issue 7/2011
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-011-9559-z

Other articles of this Issue 7/2011

Journal of Assisted Reproduction and Genetics 7/2011 Go to the issue

Gonadal Physiology and Disease

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study

Genetics

Prenatal diagnosis of Comel-Netherton syndrome with PGD, case report and review article

Gonadal Physiology and Disease

Premature ovarian failure in nobox-deficient mice is caused by defects in somatic cell invasion and germ cell cyst breakdown

Genetics

Broadening our understanding by the use of molecular cytogenetic techniques: full monosomy 21

Genetics

Reliable preimplantation genetic diagnosis in thawed human embryos vitrified at cleavage stages without biopsy

Fertility Preservation

Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone